Longer-term (96-week) efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in women

被引：0

作者：

Kityo, C. ^{[1
]}

Hagins, D. ^{[2
]}

Koenig, E. ^{[3
]}

Avihingsanon, A. ^{[4
]}

Chetchotisakd, P. ^{[5
]}

Supparatpinyo, K. ^{[6
]}

Gankina, N. ^{[7
]}

Pokrovsky, V. ^{[8
]}

Voronin, E. ^{[9
]}

Stephens, J. L. ^{[10
]}

DeJesus, E. ^{[11
]}

Wang, H. ^{[12
]}

Acosta, R. ^{[12
]}

Brainard, D. ^{[12
]}

Martin, H. ^{[12
]}

Makadzange, T. A. ^{[12
]}

机构：

[1] Joint Clin Res Ctr, Kampala, Uganda

[2] Chatham Care Ctr, Georgia Dept Publ Hlth, Savannah, GA USA

[3] Inst Dominicano Estudios Virol IDEV, Dr Pineyro 211, Santo Domingo, Dominican Rep

[4] Thai Red Cross AIDS Res Ctr, HIV Netherlands Australia Thailand Res Collaborat, Bangkok, Thailand

[5] Srinagarind Hosp, Khon Kaen, Thailand

[6] Chiang Mai Univ, Chiang Mai, Thailand

[7] Krasnoyarsk Terr Ctr Prevent & Control AIDS & Inf, Krasnoyarsk, Russia

[8] Ctr Prevent & Control AIDS, Moscow, Russia

[9] Republican Clin Infect Hosp, Minist Hlth Russian Federat, Fed State Inst, St Petersburg, Russia

[10] Mercer Univ, Sch Med, Macon, GA 31207 USA

[11] Orlando Immunol Ctr, Orlando, FL USA

[12] Gilead Sci, Foster City, CA USA

来源：

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2019年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

MOAB0106

引用

页码：4 / 4

页数：1

共 50 条

[1] Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in women
Kityo, C.
Koenig, E.
Avihingsanon, A.
Supparatpinyo, K.
DeJesus, E.
Wang, H.
Quirk, E.
Martin, H.
Elliott, C.
Makadzange, T.
HIV MEDICINE, 2018, 19 : S30 - S30
[2] Hepatic safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)
Johnson, M.
Taylor, S.
Wei, X.
Collins, S.
Martin, H.
HIV MEDICINE, 2019, 20 : 40 - 40
[3] Pharmacokinetics, safety and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed pregnant women with HIV
Zhang, H.
Martin, H.
Lin, L.
Davis, M.
Huang, H.
Xiao, D.
Arora, P.
Avihingsanon, A.
Koenig, E.
Palaparthy, R.
Girish, S.
Marathe, D.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2023, 26
[4] Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naive adults
Orkin, C.
Sax, P.
Arribas, J.
Gupta, S.
Martorell, C.
Stephens, J.
Stellbrink, H-J
DeJesus, E.
Maggiolo, F.
Huang, H.
Acosta, R.
Brainard, D.
Collins, S.
Martin, H.
HIV MEDICINE, 2020, 21 : 18 - 18
[5] Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naive adults
Orkin, C.
Sax, P. E.
Arribas, J.
Gupta, S.
Martorell, C.
Stephens, J. L.
Stellbrink, H-J
Dejesus, E.
Maggiolo, F.
Huang, H.
Acosta, R.
Brainard, D. M.
Collins, S. E.
Martin, H.
HIV MEDICINE, 2019, 20 : 94 - 95
[6] Metabolic effects of switching to tenofovir alafenamide/emtricitabine/bictegravir (B/F/TAF) from tenofovir difumarate (TDF) or tenofovir alafenamide (TAF) sparing regimens: METABIC study
Busca, C.
Ortega, D.
Martin-Carbonero, L.
Mican, R.
Ramos, L.
Valencia, M.
Montejano, R.
Montes, M.
Diaz-Almiron, M.
Delgado, A.
Bernardino, J.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 150 - 151
[7] Switching to a single-tablet regimen bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG) plus emtricitabine and either tenofovir alafenamide or tenofovir disoproxil fumarate (F/TAF or F/TDF)
Sax, P. E.
Rockstroh, J.
Luetkemeyer, A.
Yasdanpanah, Y.
Ward, D.
Trottier, B.
Rieger, A.
Liu, H.
Acosta, R.
Collins, S. E.
Brainard, D.
Martin, H.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 3 - 4
[8] Longer term safety of emtricitabine/tenofovir alafenamide (F/TAF) and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): DISCOVER trial week 96 results
Ogbuagu, O.
Podzamczer, D.
Salazar, L.
Henry, K.
Asmuth, D.
Wohl, D.
Gilson, R.
Shao, Y.
Ebrahimi, R.
Carter, C.
Das, M.
McCallister, S.
Brunetta, J.
Kronborg, G.
Reeves, I.
Spinner, C.
HIV MEDICINE, 2020, 21 : 12 - 12
[9] Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in combination with boosted darunavir (DRV) in treatment experienced patients with HIV
Hill, L.
Momper, J.
Abulhosn, K.
Ballard, C.
Young, M.
HIV MEDICINE, 2019, 20 : 81 - 81
[10] Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-infected, virologically suppressed adults
Raffi, Francois
Orkin, Chloe
Clarke, Amanda
Slama, Laurence
Gallant, Joel
Daar, Eric
Yan, Mingjin
Abram, Michael E.
Friborg, Sandra
Cheng, Andrew
Rhee, Martin
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19

← 1 2 3 4 5 →